Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sodium Cridanimod + Progestin in PrR-Negative Endometrial Cancer
NCT02064725Phase 2Unknown
- Sponsor
- AS Kevelt
- Start
- Sep 2014
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of cridanimod in endometrial carcinoma, sponsored by AS Kevelt. Primary endpoint: Objective Response Rate at 12 months. Status: unknown.
02
Drugs
cridanimod
03
Conditions
endometrial carcinoma
Beyond the preview
Go deeper on NCT02064725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02064725.